Compare DRIO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | ACRV |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.2M | 82.7M |
| IPO Year | N/A | 2022 |
| Metric | DRIO | ACRV |
|---|---|---|
| Price | $11.89 | $2.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $50.00 | $14.67 |
| AVG Volume (30 Days) | 31.4K | ★ 531.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,732,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.02 | $805.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $5.94 | $1.05 |
| 52 Week High | $31.00 | $8.00 |
| Indicator | DRIO | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 59.17 |
| Support Level | $11.77 | $2.44 |
| Resistance Level | $13.30 | $2.73 |
| Average True Range (ATR) | 0.90 | 0.17 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 20.00 | 64.91 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.